By: Adam Feuerstein | 08/26/14 - 07:00 AM EDT
Biotech stocks are booming again.
The iShares Nasdaq Biotechnology ETF (IBB) closed at 272.63 Monday, less than one point below the year (and all-time) closing high reached on Feb. 25. The sector's steep sell off in March and April are a distant memory. Roche's (RHHBY) acquisition of InterMune (ITMN) has put some M&A oomph into biotech stocks.
As you'd expect, biotech stocks are out-performing the S&P 500.
The S&P Biotech ETF (XBI) is also showing a strong recovery but not as much as the IBB given the former's broader exposure to small-cap stocks.
Gilead Sciences (GILD) leads the biotech big caps by a wide margin:
12/19/14 - 04:16 PM EST
12/19/14 - 08:25 AM EST
12/16/14 - 11:20 AM EST
12/15/14 - 09:23 AM EST
12/03/14 - 04:01 PM EST
12/21/14 - 13:32 PM EST
12/20/14 - 14:14 PM EST
12/19/14 - 10:16 AM EST
12/18/14 - 10:31 AM EST
12/17/14 - 10:07 AM EST
Access the tool that DOMINATES the Russell 2000 and the S&P 500.